{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=4",
    "query": {
      "condition": "Adenosine",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 152,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T12:49:08.133Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04381832",
      "title": "Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms, Castration-Resistant",
        "Androgen-Resistant Prostatic Neoplasms",
        "Castration Resistant Prostatic Neoplasms",
        "Prostatic Cancer, Castration-Resistant"
      ],
      "interventions": [
        {
          "name": "Etrumadenant",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Quemliclustat",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "SG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 173,
      "start_date": "2020-07-07",
      "completion_date": "2024-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 17,
      "location_summary": "Cerritos, California • Encino, California • Orange, California + 14 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04381832"
    },
    {
      "nct_id": "NCT00018018",
      "title": "Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "CD34+ cells transduced with ADA retrovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 8,
      "start_date": "2001-06-20",
      "completion_date": "2014-09-17",
      "has_results": false,
      "last_update_posted_date": "2019-12-12",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00018018"
    },
    {
      "nct_id": "NCT00179010",
      "title": "AMP as a Better Delivery System of Adenosine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ischemia"
      ],
      "interventions": [
        {
          "name": "Adenosine",
          "type": "DRUG"
        },
        {
          "name": "Adenosine Mono Phosphate (AMP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2003-10",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179010"
    },
    {
      "nct_id": "NCT03055858",
      "title": "AMPLATZER Duct Occluder II Additional Sizes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Patent Ductus Arteriosus"
      ],
      "interventions": [
        {
          "name": "ADO II AS (PDA closure)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Days and older"
      },
      "enrollment_count": 200,
      "start_date": "2017-06-05",
      "completion_date": "2022-04-05",
      "has_results": true,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Orlando, Florida • Detroit, Michigan + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03055858"
    },
    {
      "nct_id": "NCT00580905",
      "title": "Role of Adenosine in the Release of VEGF and Cytokines",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Adenosine",
          "type": "DRUG"
        },
        {
          "name": "Sodium Nitroprusside",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 8,
      "start_date": "2007-06",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2018-02-28",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00580905"
    },
    {
      "nct_id": "NCT05408845",
      "title": "Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Salivary Gland Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Stage III Major Salivary Gland Cancer AJCC v8",
        "Stage IV Major Salivary Gland Cancer AJCC v8",
        "Unresectable Salivary Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2023-03-03",
      "completion_date": "2033-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 154,
      "location_summary": "Birmingham, Alabama • Duarte, California • Dublin, California + 127 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05408845"
    },
    {
      "nct_id": "NCT02565173",
      "title": "Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "trabodenoson 4.5% BID",
          "type": "DRUG"
        },
        {
          "name": "trabodenoson 6.0% QD",
          "type": "DRUG"
        },
        {
          "name": "trabodenoson 3.0% QD",
          "type": "DRUG"
        },
        {
          "name": "timolol 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "placebo BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 303,
      "start_date": "2015-09",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2016-12-06",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 1,
      "location_summary": "Lexington, Massachusetts",
      "locations": [
        {
          "city": "Lexington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02565173"
    },
    {
      "nct_id": "NCT03878069",
      "title": "Registry Study of Revcovi Treatment in Patients With ADA-SCID",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenosine Deaminase Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "elapegademase-lvlr",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "0 Months to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2019-09-30",
      "completion_date": "2023-01-18",
      "has_results": true,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03878069"
    },
    {
      "nct_id": "NCT07224269",
      "title": "Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Adenosine Triphosphate Activities"
      ],
      "interventions": [
        {
          "name": "Terazosine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-08-12",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224269"
    },
    {
      "nct_id": "NCT04296942",
      "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer",
        "HER2+ Breast Cancer",
        "Hormone Receptor Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Brachyury-TRICOM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Entinostat",
          "type": "DRUG"
        },
        {
          "name": "M7824",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ado-trastuzumab emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-05-04",
      "completion_date": "2021-10-22",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-11-04T12:49:08.133Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04296942"
    }
  ]
}